Home » Ariad Blood-Cancer Drug’s 46 Percent Success Rate May Prompt FDA Approval Boost
Ariad Blood-Cancer Drug’s 46 Percent Success Rate May Prompt FDA Approval Boost
Ariad Pharmaceuticals’ experimental drug ponatinib spurred a positive response in 47 percent of chronic myeloid leukemia patients, a pivotal study the company said may help the medicine gain approval as a new therapy for people without treatment options.
Bloomberg
Bloomberg
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May